About Amgen
Science
Corporate Giving
Site Map
Search
Privacy & Terms
Contact Us
Patients
Medical Professionals
Partners
Investors
Careers
Media
print
mail
Home
Reimbursement Connection®
Neulasta®
(pegfilgrastim)
Neulasta® Prescribing Information
Overview
Amgen™ Oncology Assistance
Aranesp®
(darbepoetin alfa)
Neulasta®
(pegfilgrastim)
NEUPOGEN®
(Filgrastim)
EPOGEN®
(Epoetin alfa)
Sensipar®
(cinacalcet HCl)
Enbrel®
(etanercept)
Kepivance®
(palifermin)
Kineret®
(anakinra)
Vectibix®
(panitumumab)
Main Page
Contact Reimbursement Connection®
Using Reimbursement Connection®
Providing Timely Solutions
Coverage and Reimbursement
-- Medicaid
-- Medicare
-- Private Payors
Coding and Claims
-- Forms and Documents
-- Required Documentation
-- Appealing Denied Claims
Insurer Approval Processes - Overview
-- Seeking Prior Approval From a Third-Party Insurer
-- Sample Letter of Medical Necessity
-- Documentation Guidelines
-- Tips for Filing Claims
-- How to Appeal a Denied Claim
-- Medicare's Review and Hearing Process
Patient Assistance/Support Programs - Overview
-- Information for Patients
-- Neulasta®, NEUPOGEN® and You
-- Eligibility for Benefits
-- Filing Insurance Claims
-- SAFETY NET® Foundation
-- Claims Appeals
-- Glossary
-- Eligibility Screener
Important Product Safety Information
Neulasta® Prescribing Information
Neulasta® Prescribing Information
Click here
to download the PDF version of prescribing information. (
PDF, 108 Kb
)
footer
